Orthocell (ASX: OCC) Share Price and News

Professor Wood has over 30 years' experience as a plastic and reconstructive surgeon. Her revolutionary 'spray-on skin' treatment of serious burns, invented with colleague Marie Stoner, uses a patient's own skin cells to help restore damaged skin and reduce permanent scarring. This treatment was in saving many lives in the aftermath of the Bali bombing in 2002. Professor Wood played a role in bringing this life-saving Western Australian invention to the world through the establishment of Avita Medical Inc (NASDAQ: RCEL, ASX: AVH), which has expanded RECELL's approval for clinical use to over 30 countries including the US. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children's Hospital, and the Winthrop Professor of Surgery at the University of Western Australia. Professor Wood is co-founder of the Wood Foundation, which continues her research into the treatment of burns and is a Board member of the Royal Flying Doctor Service, amongst others.

Mr Anderson has over 20 years' experience in the medical device and regenerative medicine fields with experience in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has experience in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings. Mr Anderson has a track record with over 17 years' experience in CEO and board roles. His knowledge of the regenerative medicine fields compliments his insight and know-how in taking biological therapies from research to clinical applications and market introduction.

Dr Thadhani is an Independent Non Executive director of Orthocell who has co authored more than 300 scientific publications, including articles in medical journals. Dr Thadhani has more than 30 years as a general and physician, researcher, medical administrator and commercialisation adviser and has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. Dr Thadhani has served on US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors and has acted as expert advisor to global pharmaceutical companies including Sandoz, Shore, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring. He has also secured research funding from global US healthcare companies including Amgen, Abbott, Serono, Kaneka and Genzyme.

Mr Wielen has over 30 years' in wealth management, private banking, investments, and insurance, which includes executive positions in global financial services groups. These positions allowed Mr Van Der Wielen to work in London, Luxemburg, Malaysia, Sydney and Perth, for brands such as Crown Resorts, Blackstone, HBF Health Ltd, Lloyds Banking Group, Lombard Assurance and ANZ Bank. Mr Van Der Wielen currently holds the role of Chair, Crown Perth and is a Non-Executive Director on the Blackstone owned Crown Resorts Australia Ltd. Prior to this Mr Van Der Wielen was the CEO of HBF Health Ltd for over five years. Mr Van Der Wielen also serves on the Board of the Royal Flying Doctor Service WA, was appointed by the Western Australian Government to be the inaugural Chair of the Government's Future Health Research and Innovation Fund (FHRI) and Senior Advisor Australia, for Appian Capital Advisory UK.

Mr McNulty has experience as a director of several listed and not-for-profit organizations, Mr McNulty brings a leadership experience to the Orthocell Board. He served as Managing Partner of Deloittes Perth office for over a decade and was on the Deloitte Australia Board and the Deloitte Foundation Board for many years. Mr McNulty also served in various executive roles, including as a member of Deloittes National Consulting Executive, a Relationship Partner for the WA Health team and as an Asia Pacific Energy and Resources Leader.

-

-